Objective:To study the levels of serum cystatin C(Cys-C),total bile acid(TBA),and other routine blood parameters on patients with decompensated hepatitis B cirrhosis.Methods:Study group 1 consisted of 30 patients with...Objective:To study the levels of serum cystatin C(Cys-C),total bile acid(TBA),and other routine blood parameters on patients with decompensated hepatitis B cirrhosis.Methods:Study group 1 consisted of 30 patients with hepatitis B-related decompensated cirrhosis,and study group 2 consisted of 30 patients with hepatitis B;while the control group consisted of 30 healthy people who underwent physical examination.The blood parameters were used to evaluate the clinical treatment effect of patients.Results:The TBA,Cys-C,alanine transaminase(ALT),total bilirubin(TBIL),aspartate aminotransferase(AST),and international normalized ratio(INR)in study group 1 were significantly higher than those of study group 2 and the control group;while the platelet count(PLT),hemoglobin(Hb),albumin(ALB),and estimated glomerular filtration rate(eGFR)were significantly lower in the study group 1 compared to the control group and study group 2(P<0.05).The Cys-C,PLT,TBA,AST,TBIL,and INR of patients in study group 1 who were successfully treated were significantly lower than the patients who were not successfully treated(P<0.05).Conclusion:Serum Cys-C,TBA,and routine blood parameters are useful in predicting the condition and the prognosis of patients of hepatitis B-related decompensated cirrhosis.展开更多
目的探讨血栓通注射液联合左卡尼汀对糖尿病肾病患者HGF、Cys-C、TGF-β1及内皮功能影响作用。方法选取2018年1月—2019年12月医院接受治疗的糖尿病肾病患者164例进行回顾性分析,根据不同治疗方式分为对照组和观察组,每组各82例;对照组...目的探讨血栓通注射液联合左卡尼汀对糖尿病肾病患者HGF、Cys-C、TGF-β1及内皮功能影响作用。方法选取2018年1月—2019年12月医院接受治疗的糖尿病肾病患者164例进行回顾性分析,根据不同治疗方式分为对照组和观察组,每组各82例;对照组给予左卡尼汀治疗,观察组在对照组基础上联合血栓通注射液进行治疗;对两组患者治疗后临床效果、治疗前后血糖、血脂水平、肾功能指标、内皮功能以及血清中HGF、Cys-C、TGF-β1水平表达进行比较与分析。结果两组治疗后,观察组有效率为90.24%(74/82),对照组有效率为73.17%(60/82),组间比较,观察组有效率显著高于对照组(P<0.05);两组患者治疗前FBG、2 h PBG、TG、TC比较差异无统计学意义(P>0.05),治疗后两组患者各指标较治疗前比较均得到改善,改善情况差异有统计学意义(P<0.05),组间比较,观察组改善效果更显著(P<0.05);两组患者治疗前肾功能指标Scr、BUN、UAER比较无统计学差异(P>0.05),治疗后两组患者各指标较治疗前比较均得到改善,改善情况差异有统计学意义(P<0.05),组间比较,观察组改善效果更显著(P<0.05);两组患者治疗前内皮能指标sICAM-1、ET-1比较差异无统计学意义(P>0.05),治疗后两组患者个指标较治疗前比较均得到改善,改善情况差异有统计学意义(P<0.05),组间比较,观察组改善效果更显著(P<0.05);两组患者治疗前血清中HGF、Cys-C、TGF-β1比较差异无统计学意义(P>0.05),治疗后两组患者个指标较治疗前比较均得到改善,改善情况差异有统计学意义(P<0.05),组间比较,观察组改善效果更显著(P<0.05)。结论血栓通注射液联合左卡尼汀对在糖尿病肾病患者的治疗中可显著改善患者肾功能相关指标和血管内皮功能,有效控制血糖,疗效确切,值得临床推广。展开更多
基金SPPH Incubator Fund for Development of Science and Technology(2021YJY-19)SPPH Foundation for Development of Science and Technology(2021BJ-26)International Science and Technology Cooperation Projects of Shaanxi Province(2022KW-14).
文摘Objective:To study the levels of serum cystatin C(Cys-C),total bile acid(TBA),and other routine blood parameters on patients with decompensated hepatitis B cirrhosis.Methods:Study group 1 consisted of 30 patients with hepatitis B-related decompensated cirrhosis,and study group 2 consisted of 30 patients with hepatitis B;while the control group consisted of 30 healthy people who underwent physical examination.The blood parameters were used to evaluate the clinical treatment effect of patients.Results:The TBA,Cys-C,alanine transaminase(ALT),total bilirubin(TBIL),aspartate aminotransferase(AST),and international normalized ratio(INR)in study group 1 were significantly higher than those of study group 2 and the control group;while the platelet count(PLT),hemoglobin(Hb),albumin(ALB),and estimated glomerular filtration rate(eGFR)were significantly lower in the study group 1 compared to the control group and study group 2(P<0.05).The Cys-C,PLT,TBA,AST,TBIL,and INR of patients in study group 1 who were successfully treated were significantly lower than the patients who were not successfully treated(P<0.05).Conclusion:Serum Cys-C,TBA,and routine blood parameters are useful in predicting the condition and the prognosis of patients of hepatitis B-related decompensated cirrhosis.
文摘目的探讨血栓通注射液联合左卡尼汀对糖尿病肾病患者HGF、Cys-C、TGF-β1及内皮功能影响作用。方法选取2018年1月—2019年12月医院接受治疗的糖尿病肾病患者164例进行回顾性分析,根据不同治疗方式分为对照组和观察组,每组各82例;对照组给予左卡尼汀治疗,观察组在对照组基础上联合血栓通注射液进行治疗;对两组患者治疗后临床效果、治疗前后血糖、血脂水平、肾功能指标、内皮功能以及血清中HGF、Cys-C、TGF-β1水平表达进行比较与分析。结果两组治疗后,观察组有效率为90.24%(74/82),对照组有效率为73.17%(60/82),组间比较,观察组有效率显著高于对照组(P<0.05);两组患者治疗前FBG、2 h PBG、TG、TC比较差异无统计学意义(P>0.05),治疗后两组患者各指标较治疗前比较均得到改善,改善情况差异有统计学意义(P<0.05),组间比较,观察组改善效果更显著(P<0.05);两组患者治疗前肾功能指标Scr、BUN、UAER比较无统计学差异(P>0.05),治疗后两组患者各指标较治疗前比较均得到改善,改善情况差异有统计学意义(P<0.05),组间比较,观察组改善效果更显著(P<0.05);两组患者治疗前内皮能指标sICAM-1、ET-1比较差异无统计学意义(P>0.05),治疗后两组患者个指标较治疗前比较均得到改善,改善情况差异有统计学意义(P<0.05),组间比较,观察组改善效果更显著(P<0.05);两组患者治疗前血清中HGF、Cys-C、TGF-β1比较差异无统计学意义(P>0.05),治疗后两组患者个指标较治疗前比较均得到改善,改善情况差异有统计学意义(P<0.05),组间比较,观察组改善效果更显著(P<0.05)。结论血栓通注射液联合左卡尼汀对在糖尿病肾病患者的治疗中可显著改善患者肾功能相关指标和血管内皮功能,有效控制血糖,疗效确切,值得临床推广。
